Media Articles Related to Emcyt (Estramustine)
Chronic inflammation may be linked to aggressive prostate cancer
Source: Prostate / Prostate Cancer News From Medical News Today [2014.04.18]
The presence of chronic inflammation in benign prostate tissue was associated with high-grade, or aggressive, prostate cancer, and this association was found even in those with low...
Quarter of Prostate Cancer Patients May Abandon 'Watchful Waiting' Approach
Source: MedicineNet Cancer Specialty [2014.04.18]
Title: Quarter of Prostate Cancer Patients May Abandon 'Watchful Waiting' Approach
Category: Health News
Created: 4/17/2014 12:35:00 PM
Last Editorial Review: 4/18/2014 12:00:00 AM
Per Lesion Ultrasound in Prostate Cancer Active Surveillance
Source: Medscape Radiology Headlines [2014.04.17]
For prostate cancer patients followed with active surveillance, the addition of monitoring with per lesion transrectal ultrasound could help identify patients who need intervention.
Medscape Medical News
Radical treatment for advanced prostate cancer may herald major survival advantage over conventional treatment
Source: Endocrinology News From Medical News Today [2014.04.15]
Controversial new research may overturn the standard treatment of men with advanced prostate cancer.
Longest Prostate Cancer Active Surveillance Study Promising
Source: Medscape Urology Headlines [2014.04.14]
The longest follow-up to date of active surveillance shows that it is a safe and feasible approach for as long as 20 years after diagnosis.
Medscape Medical News
Published Studies Related to Emcyt (Estramustine)
A randomized phase II trial of personalized peptide vaccine plus low dose estramustine phosphate (EMP) versus standard dose EMP in patients with castration resistant prostate cancer. [2010.07]
Personalized peptide vaccination (PPV) combined with chemotherapy could be a novel approach for many cancer patients. In this randomized study, we evaluated the anti-tumor effect and safety of PPV plus low-dose estramustine phosphate (EMP) as compared to standard-dose EMP for HLA-A2- or -A24-positive patients with castration resistant prostate cancer...
Neoadjuvant LHRH analog plus estramustine phosphate combined with three-dimensional conformal radiotherapy for intermediate- to high-risk prostate cancer: a randomized study. [2010.03]
OBJECTIVE: The objective of this study is to assess the safety and efficacy of a treatment regimen comprising neoadjuvant conventional androgen deprivation therapy (ADT) plus estramustine phosphate (EMP) combined with three-dimensional conformal radiotherapy (3D-CRT) for patients with intermediate- to high-risk prostate cancer... CONCLUSIONS: The present results indicate that the combination of neoadjuvant ADT plus EMP combined with 3D-CRT sustains freedom from PSA relapse in patients with intermediate- to high-risk prostate cancer. However, this regimen is insufficient for preventing biochemical failure, and an additional intervention such as adjuvant ADT, radiation dose escalation, or both, is required, especially for patients with a pretreatment PSA level of more than 20 ng/ml and high-grade cancer.
A randomized phase II trial of mitoxantrone, estramustine and vinorelbine or bcl-2 modulation with 13-cis retinoic acid, interferon and paclitaxel in patients with metastatic castrate-resistant prostate cancer: ECOG 3899. [2010.02.24]
BACKGROUND: To test the hypothesis that modulation of Bcl-2 with 13-cis retinoic acid (CRA)/interferon-alpha2b (IFN) with paclitaxel (TAX), or mitoxantrone, estramustine and vinorelbine (MEV) will have clinical activity in men with metastatic castrate-resistant prostate cancer (CRPC)... CONCLUSIONS: Treatment with MEV was well tolerated and demonstrated clinical activity in patients with CRPC. Given the adverse effect of CRA/IFN/TAX on QOL, the study of other novel agents that target Bcl-2 family proteins is warranted. The feasibility of measuring Bcl-2 protein in a cooperative group setting is hypothesis generating and supports further study as a marker for Bcl-2 targeted therapy. TRIAL REGISTRATION: Clinical Trials Registration number: CDR0000067865.
Phase III multi-institutional trial of adjuvant chemotherapy with paclitaxel, estramustine, and oral etoposide combined with long-term androgen suppression therapy and radiotherapy versus long-term androgen suppression plus radiotherapy alone for high-risk prostate cancer: preliminary toxicity analysis of RTOG 99-02. [2009.03.01]
CONCLUSION: TEE was associated with significantly increased toxicity during treatment. The toxicity profiles did not differ at 2 and 3 years after therapy. Toxicity is an important consideration in the design of trials using adjuvant chemotherapy for prostate cancer.
Prospective randomized study comparing docetaxel, estramustine, and prednisone with docetaxel and prednisone in metastatic hormone-refractory prostate cancer. [2008.11.10]
PURPOSE: To assess the efficacy and toxicity of the addition of estramustine to docetaxel (D) for the treatment of metastatic hormone-refractory prostate cancer... CONCLUSION: The addition of estramustine to weekly D does not provide any clinically relevant advantage. Both regimens are well tolerated, although the toxicity profile favors D without estramustine.
Clinical Trials Related to Emcyt (Estramustine)
A Study of Epirubicin With Estramustine Phosphate and Celecoxib for the Treatment of Prostate Cancer [Recruiting]
The purpose of this clinical trial is to find out the effect of epirubicin with estramustine
phosphate and celecoxib on PSA and objective response in patients with hormone resistant
prostate cancer as well as evaluating the toxicity, quality of life of this combination.
Celecoxib is an FDA approved drug to treat arthritis. Epirubicin, alone or with
estramustine phosphate has been used in the treatment of hormone resistant prostate cancer.
These drugs have demonstrated evidences of tumor blood vessel suppression and combination
of these three drugs could possibly arrest further tumor growth or even make the tumor
decrease in size.
Safety and Efficacy Study of of Docetaxel vs Docetaxel Estramustine in Hormone Refractory Prostatic Cancer [Completed]
we propose to randomize patients with hormone resistant prostate cancer between
docetaxel/estramustine/prednisone and docetaxel/prednisone in a phase II study. The principal
endpoint will be the efficacy in term of PSA response.
Docetaxel, Estramustine, and Thalidomide in Treating Patients With Prostate Cancer Previously Treated With Hormone Therapy [Active, not recruiting]
RATIONALE: Thalidomide may stop the growth of prostate cancer by stopping blood flow to the
tumor. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
they stop growing or die. Combining chemotherapy with thalidomide may kill more tumor cells.
PURPOSE: Phase II trial to study the effectiveness of combining docetaxel and estramustine
with thalidomide in treating patients who have prostate cancer previously treated with
Oral Estramustine and Oral Vinorelbine in the Treatment of Hormone-Refractory Prostate Cancer [Active, not recruiting]
Purpose: This clinical trail will combine the chemotherapy drugs, Estramustine and
Vinorelbine (Navelbine), on an intermittent therapy strategy based on PSA response in the
treatment of hormone refractory prostate cancer. The investigators will determine the
tolerable dose of (oral) vinorelbine in combination with (oral)estramustine, and evaluate the
efficacy of this treatment for patients with hormone-refractory prostate cancer.
Estramustine, Etoposide and Paclitaxel Treatment for Hormonally Responsive Adenocarcinoma of the Prostate [Active, not recruiting]
Hormonal therapy is the standard treatment for prostate cancer which has spread to other
areas of the body. Despite the high initial response rates to hormonal therapy, the vast
majority of men will develop cancer which is no longer responsive to hormone deprivation. The
average time for hormonal therapy to be effective is about 18 months. Chemotherapy
combinations which can treat the disease when it no longer responds to hormonal therapy have
been developed, but these treatments are not curative. One of these combinations is
estramustine, etoposide and paclitaxel. In men with far advanced disease, 60% will have a
decrease in their PSA or shrinkage of tumors after treatment with this chemotherapy. Despite
this, these men have all developed further disease progression requiring additional
treatment. One possible way to make chemotherapy more effective is to give it when the number
of tumor cells is smallest, and the number of cells to be killed is at a low level. One
situation in which this is true is when a man has responded to hormonal therapy any tumors
are at their smallest size. This study will test whether the addition of chemotherapy at that
time will prolong the time until the cancer becomes unresponsive to hormonal therapy.